|Bid||9.20 x 800|
|Ask||9.23 x 1200|
|Day's Range||9.19 - 9.52|
|52 Week Range||3.60 - 25.77|
|Beta (3Y Monthly)||2.12|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
DBV said late Wednesday it has submitted its Biologic License Application, or BLA, for Viaskin Peanut, which is being evaluated for treating peanut-allergic children ages 4-11. Viaskin Peanut, an epicutaneous immunotherapy, is DBV's proprietary investigational platform designed to leverage the skin to activate the immune system and induce desensitization to allergens. In December 2018, the company voluntarily withdrew its prior BLA submission after the FDA communicated the need for additional data on manufacturing procedures and controls.
DBV Technologies S.A. (EPA:DBV) shareholders should be happy to see the share price up 18% in the last month. But that...
DBV Technologies S.A. (DBVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
While the market driven by short-term sentiment influenced by uncertainty regarding the future of the interest rate environment in the US, declining oil prices and the trade war with China, many smart money investors kept their optimism regarding the current bull run in the fourth quarter, while still hedging many of their long positions. However, […]
The Brisbane company next year could have FDA and European approvals for a way to protect people with peanut allergy from accidental exposures. But competitors are numerous.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! DBV Technologies S.A. (EPA:DBV) is a stock Read More...
DBV said Wednesday after the close it has voluntarily withdrawn its Biologic License Application, or BLA, for Viaskin Peanut in children 4-11. The decision to withdraw the application was made at the behest of the FDA, which communicated its decision orally and in writing Dec. 18. Reacting to the development, Bank of America Merrill Lynch analyst Tazeen Ahmad downgraded DBV from Buy to Underperform and reduced the price target from $30 to $8.
In 2002 Pierre-Henri Benhamou was appointed CEO of DBV Technologies SA (EPA:DBV). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we’ll Read More...
Aimmune and DBV Technologies both plan to file for approval of therapies this year that seek to retrain the immune system so it doesn't overreact to peanuts. In Israel, a snack called Bamba is credited for a dramatically lower rate of peanut allergy among children. The morsels of puffed corn resemble Cheetos, except taste like peanut butter.
Shares of DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ), a clinical-stage biotech developing treatment options for food allergies, present a favorable risk-reward profile over the next 12 months, according to ...